keyword
MENU ▼
Read by QxMD icon Read
search

Radiation immune cancer

keyword
https://www.readbyqxmd.com/read/28428886/vaccination-with-inhibin-%C3%AE-provides-effective-immunotherapy-against-testicular-stromal-cell-tumors
#1
Robert Aguilar, Justin M Johnson, Patrick Barrett, Vincent K Tuohy
BACKGROUND: Testicular cancer is the most common male neoplasm occurring in men between the ages of 20 and 34. Although germ-line testicular tumors respond favorably to current standard of care, testicular stromal cell (TSC) tumors derived from Sertoli cells or Leydig cells often fail to respond to chemotherapy or radiation therapy and have a 5-year overall survival significantly lower than the more common and more treatable germ line testicular tumors. METHODS: To improve outcomes for TSC cancer, we have developed a therapeutic vaccine targeting inhibin-α, a protein produced by normal Sertoli and Leydig cells of the testes and expressed in the majority of TSC tumors...
2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28427523/combination-of-immune-checkpoint-inhibitors-and-radiotherapy-review-of-the-literature
#2
REVIEW
Alessandro Sindoni, Fabio Minutoli, Giorgio Ascenti, Stefano Pergolizzi
Literature experiences in cancer treatment usually deal with either targeting the tumour cell or the immune system, which often fail to reach the curative purposes in many solid tumours. On the other hand, one mechanism of radiation-induced tumour control is the activation of the adaptive immune system by tumour antigen release following radiotherapy. So, combining radiation therapy with immune checkpoint blockade treatment at the same time may represent a way to stimulate the adaptive immune system, with further amplification of immune responses reached through systemic immune checkpoint blockade...
May 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28420863/changes-of-systemic-immune-response-after-stereotactic-ablative-radiotherapy-sabr-first-results-of-a-prospective-study-in-early-lung-cancer-patients
#3
Jacek Rutkowski, Tomasz Ślebioda, Zbigniew Kmieć, Renata Zaucha
INTRODUCTION    Among all lung tumors non-small cell lung cancer (NSCLC) is the most common. Conventional conservative treatment in medically inoperable patients with early stage NSCLC has a poor outcome. To improve treatment efficacy stereotactic ablative radiotherapy (SABR) has been developed to enable the delivery of high-dose radiation to the tumor.  OBJECTIVES    This prospective study was conducted to confirm the hypothesis that a sudden death of cancer cells after SABR may lead to systemic immune response changes...
April 18, 2017: Polish Archives of Internal Medicine
https://www.readbyqxmd.com/read/28417311/immune-checkpoint-inhibitors-for-brain-metastases
#4
REVIEW
Aaron C Tan, Amy B Heimberger, Alexander M Menzies, Nick Pavlakis, Mustafa Khasraw
PURPOSE OF REVIEW: Metastasis of cancer to the brain typically portends a poor prognosis and often results in significant morbidity, including from the side effects of treatment. More effective therapies for patients with brain metastases are needed. The current treatment paradigm uses multiple modalities, including surgery, radiation, and in some contexts, systemic chemotherapy and immunotherapy. Immune checkpoint inhibitors are increasingly being used to treat extracranial disease, and their effectiveness in the management of brain metastases needs to be understood...
June 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28412456/dietary-proanthocyanidins-prevent-ultraviolet-radiation-induced-non-melanoma-skin-cancer-through-enhanced-repair-of-damaged-dna-dependent-activation-of-immune-sensitivity
#5
REVIEW
Santosh K Katiyar, Harish C Pal, Ram Prasad
Numerous plant products have been used to prevent and manage a wide variety of diseases for centuries. These products are now considered as promising options for the development of more effective and less toxic alternatives to the systems of medicine developed primarily in developed countries in the modern era. Grape seed proanthocyanidins (GSPs) are of great interest due to their anti-carcinogenic effects that have been demonstrated using various tumor models including ultraviolet (UV) radiation-induced non-melanoma skin cancer...
April 12, 2017: Seminars in Cancer Biology
https://www.readbyqxmd.com/read/28411277/long-term-survival-in-glioblastoma-with-cytomegalovirus-pp65-targeted-vaccination
#6
Kristen A Batich, Elizabeth A Reap, Gary E Archer, Luis Sanchez-Perez, Smita K Nair, Robert J Schmittling, Pam Norberg, Weihua Xie, James E Herndon, Patrick Healy, Roger E McLendon, Allan H Friedman, Henry S Friedman, Darell Bigner, Gordana Vlahovic, Duane A Mitchell, John H Sampson
Purpose: Patients with glioblastoma have less than 15-month median survival despite surgical resection, high-dose radiation, and chemotherapy with temozolomide. We previously demonstrated that targeting cytomegalovirus pp65 using dendritic cells (DC) can extend survival and, in a separate study, that dose-intensified temozolomide (DI-TMZ) and adjuvant granulocyte macrophage colony-stimulating factor (GM-CSF) potentiate tumor-specific immune responses in patients with glioblastoma. Here, we evaluated pp65-specific cellular responses following DI-TMZ with pp65-DCs and determined the effects on long-term progression-free survival (PFS) and overall survival (OS)...
April 15, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28409192/can-local-radiotherapy-and-il-12-synergise-to-overcome-the-immunosuppressive-tumor-microenvironment-and-allow-in-situ-tumor-vaccination
#7
Gaël Deplanque, Keyvan Shabafrouz, Michel Obeid
The abscopal effect, which is the spontaneous regression of tumors or metastases outside the radiation field, occurs rarely in cancer patients. Interestingly, radiotherapy (RT) triggers an immunogenic cell death (ICD) that is able to generate tumor-specific cytotoxic CD8(+) T cells that are efficient in killing cancer cells. The key question is: why is this "abscopal effect" so uncommon in cancer patients treated with RT? Most probably, the main reason may be related to the highly immunosuppressive tumor microenvironment of well-established tumors that constantly antagonizes the anti-tumor immune responses triggered by RT...
April 13, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/28404915/prognostic-significance-of-tumor-infiltrating-immune-cells-and-pd-l1-expression-in-esophageal-squamous-cell-carcinoma
#8
Yubo Jiang, Anthony W I Lo, Angela Wong, Wenfeng Chen, Yan Wang, Li Lin, Jianming Xu
Programmed death-1 receptor (PD-1) and its ligand (PD-L1) play an integral role in regulating the immune response against cancer. This study investigated the prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating immune cells (TILs) in the tumor microenvironment in Chinese patients with esophageal squamous cell carcinoma (ESCC). Archival formalin-fixed, paraffin-embedded ESCC samples from treatment-naïve patients with ESCC after surgery or by diagnostic endoscopic biopsy were collected between 2004 and 2014...
February 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28394318/the-evolving-concept-of-cancer-stem-like-cells-in-thyroid-cancer-and-other-solid-tumors
#9
Heather Hardin, Ranran Zhang, Holly Helein, Darya Buehler, Zhenying Guo, Ricardo V Lloyd
The cancer stem-like cell (CSC) hypothesis postulates that a small population of cells in a cancer has self-renewal and clonal tumor initiation properties. These cells are responsible for tumor initiation, growth, recurrence and for resistance to chemotherapy and radiation therapy. CSCs can be characterized using markers such as SSEA-1, SSEA-4, CD44, CD24, ALDEFLUOR and others. CSCs form spheres when they are cultured in serum-free condition in low attachment plates and can generate tumors when injected into immune-deficient mice...
April 10, 2017: Laboratory Investigation; a Journal of Technical Methods and Pathology
https://www.readbyqxmd.com/read/28387388/new-frontiers-in-oncology-immune-checkpoint-inhibitors-in-combination-therapy
#10
G Romano, A Gawlinski
Substantial progress has been achieved in recent years in the field of cancer immunotherapy, with various strategies employed to elicit a host immune response against the tumor. Monoclonal antibodies have been successfully utilized in clinical trials to block key mediators of immune checkpoint pathways, including cytotoxic T-lymphocyte antigen 4, programmed cell death protein 1 and programmed cell death 1 ligand 1. Patients with a range of malignancies have been treated in these clinical trials, and significant benefits were reported among the majority of participants...
February 2017: Drugs of Today
https://www.readbyqxmd.com/read/28385367/-radiation-induced-bronchiolitis-obliterans-with-organizing-pneumonia
#11
J Ducray, S Vignot, A Lacout, I Pougnet, P-Y Marcy, C Chapellier, N Foray, A Creisson, J Thariat
Bronchiolitis obliterans with organizing pneumonia is an inflammatory reaction that can occur as a consequence of various pulmonary affections. Radiotherapy is not the sole and systematic cause of bronchiolitis obliterans with organizing pneumonia. Radiation-induced should not be confused with post-radiation, dose-dependent, inflammatory pulmonary fibrosis, which is non-immunological and located within the irradiation field. The role of immunity, local inflammation and individual radiosensitivity in bronchiolitis obliterans with organizing pneumonia is not well defined...
April 3, 2017: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
https://www.readbyqxmd.com/read/28376884/cancer-immunotherapies-targeting-the-pd-1-signaling-pathway
#12
REVIEW
Yoshiko Iwai, Junzo Hamanishi, Kenji Chamoto, Tasuku Honjo
Immunotherapy has recently emerged as the fourth pillar of cancer treatment, joining surgery, radiation, and chemotherapy. While early immunotherapies focused on accelerating T-cell activity, current immune-checkpoint inhibitors take the brakes off the anti-tumor immune responses. Successful clinical trials with PD-1 monoclonal antibodies and other immune-checkpoint inhibitors have opened new avenues in cancer immunology. However, the failure of a large subset of cancer patients to respond to these new immunotherapies has led to intensified research on combination therapies and predictive biomarkers...
April 4, 2017: Journal of Biomedical Science
https://www.readbyqxmd.com/read/28376571/immunotherapy-of-cancer
#13
Joseph A Trapani, Phillip K Darcy
BACKGROUND: For 50 years, cancer physicians have relied on just three primary treatment modalities: surgery, radiation therapy and chemotherapy. Over that time, enormous progress has been made in understanding cancer biology, targeted anti-cancer drugs have emerged, and thousands of clinical trials have taught us how best to craft treatment combinations that improve clinical outcomes. Only five years ago, a fourth and radically different form of therapy finally emerged: immune‑based cancer therapies...
2017: Australian Family Physician
https://www.readbyqxmd.com/read/28373005/avelumab-for-patients-with-previously-treated-metastatic-or-recurrent-non-small-cell-lung-cancer-javelin-solid-tumor-dose-expansion-cohort-of-a-multicentre-open-label-phase-1b-trial
#14
James L Gulley, Arun Rajan, David R Spigel, Nicholas Iannotti, Jason Chandler, Deborah J L Wong, Joseph Leach, W Jeff Edenfield, Ding Wang, Hans Juergen Grote, Anja von Heydebreck, Kevin Chin, Jean-Marie Cuillerot, Karen Kelly
BACKGROUND: Avelumab, a human Ig-G1 monoclonal antibody targeting PD-L1 and approved in the USA for the treatment of metastatic Merkel cell carcinoma, has shown antitumour activity and an acceptable safety profile in patients with advanced solid tumours in a dose-escalation phase 1a trial. In this dose-expansion cohort of that trial, we assess avelumab treatment in a cohort of patients with advanced, platinum-treated non-small-cell lung cancer (NSCLC). METHODS: In this dose-expansion cohort of a multicentre, open-label, phase 1 study, patients with progressive or platinum-resistant metastatic or recurrent NSCLC were enrolled at 58 cancer treatment centres and academic hospitals in the USA...
March 31, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28371614/hypermutations-in-gliomas-a-potential-immunotherapy-target
#15
Gaetano Finocchiaro, Tiziana Langella, Cristina Corbetta, Serena Pellegatta
Checkpoint inhibitors, like ipilimumab, nivolumab, and pembrolizumab, have provided a breakthrough in cancer immunotherapy, such as in the treatment of melanoma and colorectal and lung cancer. The close relationship between the number of mutations (mutational load) and the response to checkpoint immunotherapy has been convincingly demonstrated in these cancers. Hypermutations in tumors are caused by environmental factors, like UV radiations or cigarette smoking, or by germinal mutations affecting genes of the Mismatch Repair (MMR) machinery, as in the Lynch syndrome...
February 2017: Discovery Medicine
https://www.readbyqxmd.com/read/28368668/immunotherapy-for-head-and-neck-cancer-the-future-of-treatment
#16
Xiujie Xie, Wendi O'Neill, Quintin Pan
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide with >500,000 cases diagnosed each year. HNSCC patients often present to the clinic with advanced disease and are managed with a multi-disciplinary approach consisting of surgery, chemotherapy, and/or radiation. Morbidity and quality of life issues are major challenges in this patient population due to the debilitating effects of standard of care treatment paradigms. There is a critical need for new therapeutic approaches to manage HNSCC with better anti-tumor activities and toxicity profiles...
April 11, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28366756/clinical-determinants-of-durable-clinical-benefit-of-pembrolizumab-in-veterans-with-advanced-non-small-cell-lung-cancer
#17
Angel Qin, Lindsay Street, Kemp Cease, Benjamin L Viglianti, Edus H Warren, Lili Zhao, Nithya Ramnath
BACKGROUND: Because of the prevalence of smoking in the veteran population, non-small-cell lung cancer (NSCLC) remains a significant cause of morbidity and mortality. The objectives of our study were to evaluate the extent of durable clinical benefit (DCB) to pembrolizumab in veterans with metastatic NSCLC and to identify clinical determinants of DCB. MATERIALS AND METHODS: Prospective clinical data on veterans receiving pembrolizumab were collected. Duration of response was calculated from the first date of infusion until date of disease progression on computed tomography scans, defined according to Response Evaluation Criteria in Solid Tumors version 1...
February 9, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28366014/promising-immunotherapies-for-esophageal-cancer
#18
Tomokazu Tanaka, Jun Nakamura, Hirokazu Noshiro
Esophageal cancer (EC) is the eighth most common cancer in the world, and the prognosis of EC is still poor. Although immunotherapy has been developed in melanoma and lung cancer, it is also expected to show efficacy in EC. Currently, several clinical trials are ongoing to evaluate the safety and efficacy of immunotherapies, immune checkpoint inhibitors, adoptive T cell transfer, and therapeutic cancer vaccines in EC. Areas covered: This review provides an overview and the status of immunotherapy in EC. Clinical significance of molecules related immune checkpoints, especially PD-1 and PD-L1 is presented and the designs, results and future directions of clinical trials using immunotherapy in EC are provided...
April 1, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28361232/cancer-immunotherapy-how-low-level-ionizing-radiation-can-play-a-key-role
#19
REVIEW
Marek K Janiak, Marta Wincenciak, Aneta Cheda, Ewa M Nowosielska, Edward J Calabrese
The cancer immunoediting hypothesis assumes that the immune system guards the host against the incipient cancer, but also "edits" the immunogenicity of surviving neoplastic cells and supports remodeling of tumor microenvironment towards an immunosuppressive and pro-neoplastic state. Local irradiation of tumors during standard radiotherapy, by killing neoplastic cells and generating inflammation, stimulates anti-cancer immunity and/or partially reverses cancer-promoting immunosuppression. These effects are induced by moderate (0...
March 30, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/28357914/short-review-of-potential-synergies-of-immune-checkpoint-inhibition-and-radiotherapy-with-a-focus-on-hodgkin-lymphoma-radio-immunotherapy-opens-new-doors
#20
Christian Baues, Maike Trommer-Nestler, Karolina Jablonska, Paul J Bröckelmann, Max Schlaak, Michael von Bergwelt-Baildon, Andreas Engert, Robert Semrau, Simone Marnitz, Sebastian Theurich
Radiotherapy is an established local treatment in patients with various malignancies. Systemic responses following local irradiation have been described as abscopal effects. Modern cancer immunotherapy with immune checkpoint inhibitors has shown impressive response rates and prolongation of survival even in heavily pretreated patients with advanced solid malignancies and lymphomas. Radiotherapy has been shown to modulate immune response, and its application in the context of immune checkpoint inhibition has recently evolved into an active field of research...
March 2017: Immunotherapy
keyword
keyword
70287
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"